While the generics sector is currently wrapped up in the love triangle between Teva, Mylan and Perrigo, Endo International has revealed its interest through the $8bn (€7bn) acquisition of Par Pharmaceutical, creating what it says is “a generics business that is one of the industry's fastest growing” and among the top five in the US based on combined sales.
“Our generics business, Qualitest, continues to be an extremely attractive and effective growth driver for Endo,” said CEO Rajiv De Silva.
“This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products while also transforming Endo, creating a powerful corporate platform for future growth and strategic M&A.”
Par’s portfolio includes over 100 across multiple dosage forms - including oral solids, oral suspensions, and injectables – while there are over 200 Abbreviated New Drug Applications (ANDAs) in the pipeline.
Endo will add 1,900 staff members across Par’s infrastructure, which includes manufacturing and R&D sites in New York, California, Michigan, Connecticut, and Chennai (India).
Lupin in Brazil
India-based API and drugmaker Lupin has expanded its global presence through the acquisition of Medquímica Indústria Farmacêutica, a Brazilian branded generics and OTC maker.
“There are a lot of synergies to the acquisition and Lupin would not only leverage its research & technology strengths to build a high quality product pipeline but also use Medquímica’s commercial presence to expand business by targeting niche high-growth therapy segments,” Lupin CEO Vinita Gupta, said, commenting on her firm’s entry into Brazil.
“The acquisition is also a reflection of Lupin’s commitment to expand into the Latin American market and an important part of Lupin’s Emerging Markets play going forward.”
B-I and Pharmaxis
And finally this week, Boehringer-Ingelheim has expanded its pipeline through an upfront payment of €27.5m to Australia’s Pharmaxis for the investigational anti-inflammatory drug candidate PXS4728A.
PXS4728A is an oral small molecule inhibitor of vascular adhesion protein-1 currently in Phase I clinical trials for treating non-alcoholic steatohepatitis (NASH), though the firm says it has further potential in chronic obstructive pulmonary disease (COPD).
“With a total potential value in excess of $A750m ($600m), it is a globally competitive deal and significant for the Australian biotech sector,” said Pharmaxis CEO Gary Phillips. “Boehringer Ingelheim's clinical expertise will now be applied to the development of this drug which has the potential to make a real difference in the treatment of diseases with high unmet clinical need.”